May 31, 2019

GenomeWeb Reports a feature story on QuanDx HPV testing by Dartmouth research group led by Dr. Tsongalis

Unexpected Prevalence of Rare High-Risk HPV Types Demonstrates Utility of Zeesan Biotech Assay in Low-Resource Setting May 29, 2019 | Madeleine Johnson NEW YORK (GenomeWeb) – […]
May 28, 2019

QuanDx/Zeesan Biotech’s MeltPro High Risk HPV Genotyping Assay is Effective for Cervical Cancer Screening for Women in Low- and Middle-Income Countries

San Jose, CA, USA. May 21, 2019 – QuanDx is the designated U.S. distributor of a PCR-based assay from Zeesan Biotech designed to detect and identify […]
January 11, 2016

QuanDx Raises $3.0 Million in Series B2 Financing

San Jose, CA, USA. Jan. 11, 2016 QuanDx Inc., a biotechnology company developing and commercializing innovative molecular diagnostic tests for personalized cancer treatment, today announced that […]
November 24, 2015

QuanDx Announces Distribution Agreement for the Zeesan CE-IVD High Risk HPV Genotyping Assay

San Francisco, CA, USA. Nov. 24, 2015 QuanDx Inc., a biotechnology company developing and commercializing innovative molecular diagnostic tests for personalized cancer treatment, today announced that […]
September 24, 2015

See you at AMP annual meeting in Austin, TX

San Francisco, CA, USA. Sept. 24th, 2015 QuanDx Inc., a biotechnology company developing and commercializing innovative molecular diagnostic tests for personalized cancer treatment, welcome you to […]
March 10, 2015

QuanDx Announces Appointment of Resnova S.r.l as its Italian Distribution Partner

Menlo Park, CA, USA. Mar. 10th, 2015 QuanDx Inc, a Biotechnology Company developing and commercializing innovative molecular diagnostic tests, announced that Resnova S.r.l. a Rome based […]